Skip to Content
Merck
CN
  • Pioglitazone inhibits angiotensin II-induced atrial fibroblasts proliferation via NF-κB/TGF-β1/TRIF/TRAF6 pathway.

Pioglitazone inhibits angiotensin II-induced atrial fibroblasts proliferation via NF-κB/TGF-β1/TRIF/TRAF6 pathway.

Experimental cell research (2014-08-26)
Xiao-qing Chen, Xu Liu, Quan-xing Wang, Ming-jian Zhang, Meng Guo, Fang Liu, Wei-feng Jiang, Li Zhou
ABSTRACT

The exact mechanisms underlying inhibitory effects of pioglitazone (Pio) on Angiotensin II (AngII)-induced atrial fibrosis are complex and remain largely unknown. In the present study, we examined the effect of Pio on AngII-induced mice atrial fibrosis in vivo and atrial fibroblasts proliferation in vitro. In vivo study showed that AngII infusion induced atrial fibrosis and increased expressions of Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) and tumor necrosis factor receptor associated factor 6 (TRAF6) in mice models. However, those effects could be attenuated by Pio (P<0.01). As for in vitro experiment, Pio suppressed AngII-induced atrial fibroblasts proliferation via nuclear factor-κB/transforming growth factor-β1/TRIF/TRAF6 signaling pathway in primary cultured mice atrial fibroblasts (P<0.01). In conclusion, suppression of Pio on AngII-induced atrial fibrosis might be related to its inhibitory effects on above signaling pathway.

MATERIALS
Product Number
Brand
Product Description

Pioglitazone for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Pioglitazone hydrochloride, United States Pharmacopeia (USP) Reference Standard
Pioglitazone hydrochloride, European Pharmacopoeia (EP) Reference Standard